Premium
Disseminated aspergillosis in an adolescent with acute lymphoblastic leukemia
Author(s) -
Zwitserloot Annelies M.,
Warris Adilia,
van't Hek Louis G.,
van Die Lya E.,
Verweij Paul E.,
MavinkurveGroothuis Annelies M.C.
Publication year - 2008
Publication title -
pediatric blood and cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.116
H-Index - 105
eISSN - 1545-5017
pISSN - 1545-5009
DOI - 10.1002/pbc.21601
Subject(s) - medicine , aspergillosis , voriconazole , caspofungin , leukemia , lymphoblastic leukemia , acute leukemia , antifungal , intensive care medicine , pediatrics , immunology , dermatology
Disseminated aspergillosis in immunocompromised patients has a mortality rate of almost 100%. Despite the development of new antifungal agents, the outcome of disseminated aspergillosis has only improved slightly, particular in patients with central nervous system (CNS) involvement. The use of combination antifungal therapy might improve the dismal outcome of disseminated aspergillosis. We describe a critically ill adolescent with acute lymphoblastic leukemia who was successfully treated with voriconazole and caspofungin for disseminated aspergillosis with involvement of the lung, brain and thyroid gland. Pediatr Blood Cancer 2008;51:423–426. © 2008 Wiley‐Liss, Inc.